The Drug Induced Renal Injury Consortium
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Renal Impairment / Chronic Kidney Disease, Hospital |
| Therapuetic Areas: | Nephrology / Urology, Other |
| Healthy: | No |
| Age Range: | 2 - Any |
| Updated: | 4/2/2016 |
| Start Date: | February 2013 |
| End Date: | December 2015 |
| Contact: | Linda Awdishu, PharmD |
| Email: | lawdishu@ucsd.edu |
| Phone: | 619-471-0749 |
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Some medications are known to cause kidney damage because the person is allergic to the
medication while others cause direct damage to the kidney because they are toxic at certain
concentrations. Risk factors for developing kidney damage have been identified for some
medications but not for all. Patients who are exposed to these important medications and
develop problems with their kidneys may have some genetic risk. The purpose of this study is
to determine the genetic risk factors for drug induced kidney injury. A better understanding
of the role of genetics for the development of kidney injury from medications will allow us
to better select medications, improve effectiveness of treatment and minimize harm.
medication while others cause direct damage to the kidney because they are toxic at certain
concentrations. Risk factors for developing kidney damage have been identified for some
medications but not for all. Patients who are exposed to these important medications and
develop problems with their kidneys may have some genetic risk. The purpose of this study is
to determine the genetic risk factors for drug induced kidney injury. A better understanding
of the role of genetics for the development of kidney injury from medications will allow us
to better select medications, improve effectiveness of treatment and minimize harm.
Inclusion Criteria:
- Patients age 2 years and older
- Exposure to a candidate drug for at least 24 hours (see above)
- Patients who have developed DIRI as defined by the primary criteria
- Written informed consent or assent and consent obtained
- If patient lacks capacity to consent then surrogate consent will be obtained
Exclusion Criteria:
- Patients with a history of or have a kidney transplant
- Patients with a history of or have a bone marrow transplant
- Patients with Chronic Kidney Disease stage 5 (eGFR < 15 mL/min/1.73m2)
- Patients on 3 or more causal drugs
- Patients with no history or time course on drug exposure
- Patient who, in the opinion of the Investigator, is not suitable to participate in
the study.
- Unable to obtain written informed consent or assent
- Unable to obtain surrogate consent for patients who lack capacity
We found this trial at
8
sites
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials